PORTEC‐3 trial finds that adjuvant chemoradiotherapy significantly improves 10‐year survival for patients with high‐risk endometrial cancer
C
Carrie Printz
Article Details
Volume / Issue
Vol. 76, Issue 1
Published
January 01, 2026
ISSN
0007-9235
Publisher
Wiley
Authors (1)
C
Carrie Printz
Related Articles from this Journal
Systemic amyloid light‐chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates
Xia Wu, Heather Landau et al.
May 2026
10.3322/caac.70092
Screening for colorectal cancer
May 2026
10.3322/caac.70087
Correction to “Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases”
May 2026
10.3322/caac.70093
Blood tests for colorectal cancer—Hype ahead of evidence?
Gloria D. Coronado, David A. Lieberman
May 2026
10.3322/caac.70088
Medullary thyroid carcinoma and <i>RET</i> molecular testing: A virtual tumor board on clinical decision‐making
Lucas Kallas‐Silva, Victor Alexandre dos Santos Valsecchi et al.
May 2026
10.3322/caac.70086